These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27891631)

  • 1. Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
    Alosh M; Huque MF; Bretz F; D'Agostino RB
    Stat Med; 2017 Apr; 36(8):1334-1360. PubMed ID: 27891631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials.
    Howard G; McClure LA; Krakauer JW; Coffey CS
    Curr Opin Neurol; 2007 Feb; 20(1):71-7. PubMed ID: 17215692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction effects and subgroup analyses in clinical trials: more than meets the eye?
    Sevdalis N; Jacklin R
    J Eval Clin Pract; 2008 Oct; 14(5):919-22. PubMed ID: 18373582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup.
    Alosh M; Huque MF; Koch GG
    J Biopharm Stat; 2015; 25(6):1161-78. PubMed ID: 25331097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplicity considerations for subgroup analysis subject to consistency constraint.
    Alosh M; Huque MF
    Biom J; 2013 May; 55(3):444-62. PubMed ID: 23585158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.
    Yusuf S; Wittes J; Probstfield J; Tyroler HA
    JAMA; 1991 Jul; 266(1):93-8. PubMed ID: 2046134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis.
    Dane A; Spencer A; Rosenkranz G; Lipkovich I; Parke T;
    Pharm Stat; 2019 Mar; 18(2):126-139. PubMed ID: 30592133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.
    Yip WK; Bonetti M; Cole BF; Barcella W; Wang XV; Lazar A; Gelber RD
    Clin Trials; 2016 Aug; 13(4):382-90. PubMed ID: 27094489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel: new preparation. An alternative to aspirin.
    Prescrire Int; 1999 Dec; 8(44):163-4. PubMed ID: 11503810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.
    Brookes ST; Whitely E; Egger M; Smith GD; Mulheran PA; Peters TJ
    J Clin Epidemiol; 2004 Mar; 57(3):229-36. PubMed ID: 15066682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 14. A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker.
    Carlet J
    Intensive Care Med; 2004 May; 30(5):994; author reply 995. PubMed ID: 15083270
    [No Abstract]   [Full Text] [Related]  

  • 15. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials.
    Parker AB; Naylor CD
    Am Heart J; 2000 Jun; 139(6):952-61. PubMed ID: 10827374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes.
    Aronson D
    Thromb Haemost; 2014 Jul; 112(1):16-25. PubMed ID: 24599493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
    Minerva Med; 2003 Apr; 94(2):XIII-IV. PubMed ID: 12916522
    [No Abstract]   [Full Text] [Related]  

  • 19. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
    Zhang S; Liang F; Li W; Hu X
    J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recursive partitioning approach for subgroup identification in individual patient data meta-analysis.
    Mistry D; Stallard N; Underwood M
    Stat Med; 2018 Apr; 37(9):1550-1561. PubMed ID: 29383818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.